Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | AR | P10275 | 1/20 | 0.51 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | PPARG | P37231 | 2/20 | 0.47 |
| ▸ | PPARA | Q07869 | 2/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17724477 | 0.88 | TDP1 (0.50) | TDP1ALDH1A1TSHRNPSR1LMNA | |
| SCHEMBL10552330 | 0.87 | ALDH1A1 (0.52) | TDP1ALDH1A1TSHRNPSR1LMNA | |
| SCHEMBL16673220 | 0.86 | LMNA (0.50) | TDP1ALDH1A1TSHRNPSR1LMNA | |
| SCHEMBL10904429 | 0.86 | TDP1 (0.49) | TDP1ALDH1A1TSHRNPSR1LMNA | |
| SCHEMBL27504808 | 0.86 | PPARG (0.55) | TDP1ALDH1A1TSHRNPSR1LMNA | |
| SCHEMBL10938219 | 0.86 | TSHR (0.58) | ALDH1A1TSHRNPSR1LMNAL3MBTL1 | |
| SCHEMBL16672960 | 0.86 | TSHR (0.55) | TDP1ALDH1A1TSHRNPSR1LMNA | |
| SCHEMBL27512257 | 0.86 | AR (0.55) | TDP1ALDH1A1TSHRARNPSR1 | |
| SCHEMBL4426728 | 0.85 | L3MBTL1 (0.73) | ALDH1A1LMNAL3MBTL1SMN1; SMN2PPARG | |
| SCHEMBL4425843 | 0.85 | L3MBTL1 (0.73) | ALDH1A1LMNAL3MBTL1SMN1; SMN2PPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102428166-A | Perfume system | PROCTER & GAMBLE | 2012-04-25 | — | — | CN | claimed |
| EP-2869389-B1 | NONAQUEOUS ELECTROLYTIC SOLUTION AND NONAQUEOUS ELECTROLYTIC SOLUTION CELL USING SAME | MITSUBISHI CHEM CORP (JP) | 2019-11-13 | — | — | EP | disclosed |
| US-10320030-B2 | Nonaqueous electrolyte solution and nonaqueous electrolyte battery employing the same | MITSUBISHI CHEMICAL CORPORATION (JP) | 2019-06-11 | — | — | US | disclosed |
| CN-109310974-A | The method for being used to prepare microcapsules | 西姆莱斯股份公司 | 2019-02-05 | — | — | CN | disclosed |
| US-9623123-B2 | Fluorescent conjugated polymers with a bodipy-based backbone and uses thereof | MICHIGAN TECHNOLOGICAL UNIVERSITY (US) | 2017-04-18 | — | — | US | disclosed |
| US-20170014532-A1 | FLUORESCENT CONJUGATED POLYMERS WITH A BODIPY-BASED BACKBONE AND USES THEREOF | UNIV MICHIGAN TECH (US) | 2017-01-19 | — | — | US | disclosed |
| US-9412949-B2 | Fluorescent conjugated polymers with a bodipy-based backbone and uses thereof | MICHIGAN TECHNOLOGICAL UNIVERSITY (US) | 2016-08-09 | — | — | US | disclosed |
| US-20150140448-A1 | NONAQUEOUS ELECTROLYTE SOLUTION AND NONAQUEOUS ELECTROLYTE BATTERY EMPLOYING THE SAME | MITSUBISHI CHEMICAL CORPORATION (JP) | 2015-05-21 | — | — | US | disclosed |
| EP-2869389-A1 | NONAQUEOUS ELECTROLYTIC SOLUTION AND NONAQUEOUS ELECTROLYTIC SOLUTION CELL USING SAME | Mitsubishi Chemical Corporation (JP) | 2015-05-06 | — | — | EP | disclosed |
| US-20140107135-A1 | PYRIMIDINONE INHIBITORS OF LIPOPROTEIN-ASSOCIATED PHOSPHOLIPASE A2 | AUSPEX PHARMACEUTICALS, INC. (US) | 2014-04-17 | — | — | US | disclosed |
| US-4377668-A | PHOTORESISTS | CIBA-GEIGY CORPORATION (US) | 1983-03-22 | — | — | US | disclosed |
| US-4377669-A | PHOTORESISTS | CIBA-GEIGY CORPORATION (US) | 1983-03-22 | — | — | US | disclosed |
| US-4337200-A | INTERMEDIATES FOR PHOTORESISTS | CIBA-GEIGY CORPORATION (US) | 1982-06-29 | — | — | US | disclosed |
| US-4304907-A | Bicyclo lactone intermediates for prostaglandin analogs | THE UPJOHN COMPANY (US) | 1981-12-08 | — | — | US | disclosed |
| US-4303796-A | 16-Phenoxy prostaglandin F2α analogs | THE UPJOHN COMPANY (US) | 1981-12-01 | — | — | US | disclosed |
| US-4283509-A | ADDITION POLYMERS | CIBA-GEIGY CORPORATION (US) | 1981-08-11 | — | — | US | disclosed |
| US-4242264-A | MONOMERS FOR PHOTOCROSSLINKABLE POLYMERS | CIBA-GEIGY CORPORATION (US) | 1980-12-30 | — | — | US | disclosed |
| US-4116989-A | 16-Phenoxy prostaglandin F1α analogs | THE UPJOHN COMPANY (US) | 1978-09-26 | — | — | US | disclosed |
| US-4087616-A | 16-Phenoxy prostaglandin A2 analogs | THE UPJOHN COMPANY (US) | 1978-05-02 | — | — | US | disclosed |
| US-3931279-A | 5-Oxa prostaglandin F2.sub.α analogs | THE UPJOHN COMPANY (US) | 1976-01-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170014532-A1 | FLUORESCENT CONJUGATED POLYMERS WITH A BODIPY-BASED BACKBONE AND USES THEREOF | TLR3, TLR5, PARP15 | TDP1 2036/4885ALDH1A1 2651/4885TSHR 4562/4885 |
| US-20140107135-A1 | PYRIMIDINONE INHIBITORS OF LIPOPROTEIN-ASSOCIATED PHOSPHOLIPASE A2 | PLA2G1B, PLA2G4A, PLA2G4B | TDP1 784/4885ALDH1A1 1423/4885TSHR 3285/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.